Advisory Board
VerifiedOnline/Digital
We are a best practices firm that uses a combination of research, technology, and consulting to improve the performance of health care organizations around the world.
We forge and find the best new ideas and proven practices from across our vast network of leaders. Then we customize and hardwire them into every level of your organization, creating enduring value. Interested in membership Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
|
Similarweb UVM |
Request pricing |
|
Comscore UVM |
Request pricing |
Recent Articles
Search ArticlesRethinking vaccine access with electronic prescribing
Electronic prescribing (eRx) for vaccines is an important tool for health systems when in-office vaccination is not possible — such as when vaccines are not stocked, when coverage or reimbursement limitations apply (for example, Medicare Part D limitations), or when patients choose to receive vaccination elsewhere.
Are fermented foods more than a wellness trend?
According to a report from the Wall Street Journal, multiple members of President Trump's cabinet, including HHS Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Transportation Secretary Sean Duffy, and Vice President JD Vance, have increased their consumption of fermented foods. "Within 30 days I lost 20 pounds," Kennedy said at an event in Michigan in June.
Around the nation: Eli Lilly sues black market GLP-1 sellers
You may be receiving this error message if you are logged out. Be sure to log into your account to access the resources. Auto logout in seconds. Eli Lilly is suing six companies for allegedly selling black market versions of its experimental GLP-1 drug retatrutide, which has not yet received regulatory approval, in today's bite-sized hospital and health industry news from California, the District of Columbia, and Indiana.
Could a new mRNA vaccine help treat cancer?
"While we need to await the final results, this early report is certainly promising and builds on the encouraging results that have been observed across smaller studies over the past decade," said Catherine Wu, an oncologist at the Dana-Farber Cancer Institute.
Could this new pill be like GLP-1s without the side effects?
You may be receiving this error message if you are logged out. Be sure to log into your account to access the resources. Auto logout in seconds. Millions of people take GLP-1s for weight loss, but few stay on the drugs in the long term due to side effects. However, an experimental new drug, which has been called "exercise in a pill," could bring the benefits of GLP-1s without the downsides, helping prevent weight rebound and the loss of metabolic benefits.
Health policy roundup: Trump to nominate Heidi Overton for FDA commissioner
"By cutting off federal funds for these sex-rejecting procedures, we're following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish," said CMS Administrator Mehmet Oz in a statement. The treatments are already banned in the majority of Republican-led states and have been a topic of debate among health authorities.
Around the nation: Moderna begins human trials of Ebola vaccine
Moderna has launched a Phase 1 clinical trial of its mRNA vaccine against the Bundibugyo Ebola virus, which is currently behind a widespread outbreak in parts of Africa, in today's bite-sized hospital and health industry news from California, Massachusetts, and Rhode Island.
Beyond staffing ratios: Building assignments around real nurse workload
* By clicking submit below I agree and consent to Advisory Board collecting, using, processing, and storing my personal information including my name and email so that Advisory Board may contact me in relation to the services that I receive from Advisory Board. I acknowledge that my personal data will be stored within the United States of America which may not provide the same level of protection as my home country. This consent is valid unless I have opted out or withdrawn consent.
Value-based care demystified
Many healthcare leaders are navigating a landscape shaped by both fee-for-service and value-based reimbursement. As organizations balance payment models and face pressure to improve outcomes while managing costs, leaders are increasingly looking deeper into the concept of value-based care (VBC) to understand how to succeed in this new environment. Join us as we demystify VBC. We'll unpack: What is VBC? What does the future of VBC look like? And how will care delivery evolve under VBC?
5 strategies to advance health equity in dermatology care
You may be receiving this error message if you are logged out. Be sure to log into your account to access the resources. Auto logout in seconds. Chronic inflammatory skin diseases like alopecia areata and atopic dermatitis disproportionately affect patients from diverse communities due to barriers to access, provider training, and care delivery.